FDA Updates

The diagnostic tool can aid the identification of patients with synovial sarcoma who may be eligible for treatment with newly approved afamitresgene autoleucel.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

The RUBY trial will continue and analyze the overall population survival after treatment with the drug combination.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

The designation is based on animal model studies that have demonstrated superior efficacy in comparison to sildenafil.

If approved, the drug would be the first in a new class of medications to treat acute pain in over 20 years.

The decision is based on positive results from the PERSEUS trial.

The approval streamlines treatment administration to eliminate compounding steps, reduce preparation time, and enhance safety for clinicians.

The approval marks the first oral immunotherapy treatment to mitigate allergic reactions, including anaphylaxis.

Early identification of monoclonal gammopathy of undetermined significance leads to more efficacious disease monitoring and intervention.

The blood test offers patients advanced screening methods capable of detecting colorectal cancer in its earlier stages.

AIC100 could meet an unmet medical need to effectively treat individuals with anaplastic thyroid cancer — the most aggressive form of the disease.

In April 2017, the drug was approved to treat the slow loss of the ability to walk for symptomatic patients aged 3 and older who had Batten disease.

The decision offers patients with difficulty swallowing their medication expanded options for treatment administration.

The decision expands the use of incobotulinumtoxinA beyond treatment of frown lines.

Eculizumab-aagh does not have an interchangeable designation, though that could be updated in the future.

A large portion of the population of patients in the United States with GERD have the non-erosive type of the disease.

The drug is intended to treat individuals with metastatic or locally advanced melanoma.

Following the previous FDA approval of faricimab-svoa to treat some of the leading causes of vision loss, the Administration has approved a single-dose prefilled syringe of the drug which could lead to safer and more efficient administration while easing patient burden.

Pulsed field ablation may offer patients an efficacious treatment option with limited damage to surrounding tissues.

ADI-270 is a gamma delta CAR T-cell therapy candidate targeting CD70-positive cancers.

Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC).

The designation was approved based on interim data from a phase 1 study that assessed SV-102 among males with metastatic castrate-resistant prostate cancer (mCRPC).

This is the first novel, precision mechanism of action to be released to treat patients with CIDP in over 3 decades.

Small cell lung cancer is initially responsive to platinum-based chemotherapy, but it does develop drug resistance over time, furthering the need for better treatment options.

RCT1100 is designed to deliver DNAI1 mRNA directly to affected airways through an inhaled nebulizer and fills an urgent unmet need in the treatment of those with primary ciliary dyskinesia.

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.